Welcome to our dedicated page for Senseonics Holdings SEC filings (Ticker: SENS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Senseonics Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Senseonics Holdings's regulatory disclosures and financial reporting.
Senseonics Holdings director Douglas S. Prince received 19,673 shares of common stock on 10/01/2025 as payment under the company’s non-employee director compensation policy in lieu of quarterly retainer fees. The shares were issued using the closing price of $0.413 on the NYSE American for that date, representing the reported cash-equivalent value of $8,124.95. After the issuance, the filing reports the reporting person beneficially owned 1,107,280 shares. The Form 4 was signed by an attorney-in-fact and filed on 10/03/2025.
Douglas A. Roeder, a director of Senseonics Holdings, Inc. (SENS), received 35,714 shares of common stock under the company’s non-employee director compensation policy in lieu of quarterly cash retainer fees. The shares were issued based on the NYSE American closing price of $0.413 per share on the transaction date, representing cash-equivalent compensation of $14,749.88. After this issuance, the reporting person beneficially owned 1,694,540 shares of the issuer’s common stock. The transaction is reported on a Form 4 and was filed by a single reporting person. The Form states the issuance was pursuant to the issuer’s director compensation policy and discloses the calculation used to determine the share amount.
Senseonics Holdings director Edward Fiorentino received 34,200 shares of common stock on 10/01/2025 under the company's non-employee director compensation policy. The shares were issued in lieu of a quarterly retainer; the filing states the number of shares equals $14,124.60 divided by the closing price of $0.413 per share on the NYSE American that day.
After the issuance, the reporting person beneficially owned 1,379,301 shares. The Form 4 was signed by attorney-in-fact Frederick T. Sullivan on 10/03/2025. The filing records this as a routine equity grant to a director under the disclosed compensation policy.
Senseonics Holdings, Inc. disclosed an insider transaction on a Form 4 showing a director received 31,174 shares of common stock on October 1, 2025. The shares were issued under the non-employee director compensation policy in lieu of quarterly retainer fees, calculated as $12,874.86 divided by the $0.413 closing price on that date.
Following the transaction, the director beneficially owned 1,294,175 shares, held directly.
Senseonics Holdings, Inc. reported that its stockholders approved a proposal at a special meeting to allow the Board of Directors to implement a reverse stock split of the Company’s common stock. The approved amendments to the Amended and Restated Certificate of Incorporation permit a reverse split in a range from 1-for-10 to 1-for-20, with a proportionate reduction in the authorized number of shares of common stock, at any time prior to September 29, 2026, as determined by the Board in its sole discretion.
The proposal passed with 285,639,190 votes for, 178,232,358 votes against, and 5,014,498 abstentions, showing substantial but not unanimous support. This approval gives the Board flexibility to adjust the share count and share price structure in the future within the approved range.
Senseonics Holdings, Inc. (SENS) is asking shareholders to approve authority for its board to implement a reverse stock split at a ratio between 1-for-10 and 1-for-20, at any time before September 29, 2026. The Special Meeting will be held virtually on September 29, 2025 and the record date is August 7, 2025 when 814,680,910 shares were outstanding. The board unanimously recommends a vote FOR the proposal to give management flexibility to raise the per-share trading price, address NYSE American minimum price criteria, potentially improve marketability and liquidity, and preserve flexibility for future corporate actions. No fractional shares will be issued; holders entitled to fractions will receive cash based on the five-day average closing price before the effective date. Approval requires a majority of votes properly cast.
Senseonics Holdings, Inc. reported that Robert J. Smith and affiliated entities beneficially own a combined 50,035,000 shares of common stock, equal to 6.14% of the class. That aggregate position is composed of holdings by Energy Capital, LLC (49,700,000 shares, 6.10%) and Plato & Associates, LLC (335,000 shares, 0.04%).
The filing states Mr. Smith has sole voting and sole dispositive power over the reported shares, meaning he alone can direct voting and disposition of the position. The statement includes a certification that the securities were not acquired to change or influence control of the issuer.
Senseonics Holdings (NYSE American: SENS) has filed a Form S-3 universal shelf. The registration enables the company to issue up to $300 million in any mix of common or preferred stock, debt securities and warrants. It also includes a $100 million at-the-market (ATM) program with TD Cowen; unsold ATM capacity can be re-allocated to other offerings.
SENS is a non-accelerated, smaller reporting company with 814.7 million shares outstanding and a recent share price of $0.51 (5 Aug 2025). Proceeds are earmarked for general corporate purposes—R&D, SG&A, commercialization of the Eversense implantable CGM platform, capex and potential acquisitions—though no commitments are specified.
The filing contains no new operating results, but it signals that management may raise capital equal to roughly one-third of the current market capitalization, creating potential dilution while enhancing liquidity and strategic flexibility.